A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19 : A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19
Study duration per participant is approximately 28 days including a 14-day treatment period.
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ClinicalTrials.gov - (2022) vom: 24. März Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: November 9, 2020, Last downloaded: ClinicalTrials.gov processed this data on April 04, 2022, Last updated: April 06, 2022 |
|---|
| Study ID: |
NCT04622332 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003571521 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003571521 | ||
| 003 | DE-627 | ||
| 005 | 20230425193344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003571521 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04622332 | ||
| 035 | |a (UBBS_Klinische_Studien)SIR365-US-101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19 |b A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: November 9, 2020, Last downloaded: ClinicalTrials.gov processed this data on April 04, 2022, Last updated: April 06, 2022 | ||
| 520 | |a Study duration per participant is approximately 28 days including a 14-day treatment period | ||
| 650 | 2 | |a Coronavirus Infections | |
| 650 | 4 | |a Medical Condition: Corona Virus Infection | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 1 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2022) vom: 24. März |
| 773 | 1 | 8 | |g year:2022 |g day:24 |g month:03 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04622332 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 24 |c 03 | ||